-
SAb Biotherapeutics Rebrands as SAB BIO (opens in a new tab)
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1…
-
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions (opens in a new tab)
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a…
-
SAB Biotherapeutics Announces Departure of Chief Financial Officer (opens in a new tab)
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a…
-
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics (opens in a new tab)
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB…
-
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates (opens in a new tab)
MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company…
-
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors (opens in a new tab)
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a…
-
SAB Biotherapeutics Provides SAB-142 Trial Update (opens in a new tab)
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage…
-
SAB Biotherapeutics to Present at INNODIA Annual Meeting (opens in a new tab)
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage…
-
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference (opens in a new tab)
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical…
-
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results (opens in a new tab)
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB -142…
-
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment (opens in a new tab)
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage…
-
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference (opens in a new tab)
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage…